News features

AC Immune CEO Andrea Pfeifer outlines why AC Immune still believes that Abeta plays a major role in Alzheimer’s disease and how strategies for developing successful therapeutic interventions are shifting.
Read full article...

AC Immune CEO Andrea Pfeifer outlines why AC Immune still believes that Abeta plays a major role in Alzheimer’s disease and how strategies for developing successful therapeutic interventions are shifting.

AC Immune CEO Andrea Pfeifer outlines why AC Immune still believes that Abeta plays a major role in Alzheimer’s disease and how strategies for developing successful therapeutic interventions...

AC Immune CEO Andrea Pfeifer outlines why AC Immune still believes that Abeta plays a major role in Alzheimer’s disease and how strategies for developing successful therapeutic interventions are shifting.

AC Immune CEO Andrea Pfeifer encouraged to see Genentech broaden its clinical evaluation of RO710570, a monoclonal antibody designed to stop the cell-to-cell spared of toxic forms of Tau protein.
Read the article in English: Article...

AC Immune CEO Andrea Pfeifer encouraged to see Genentech broaden its clinical evaluation of RO710570, a monoclonal antibody designed to stop the cell-to-cell spared of toxic forms of Tau protein.

Webcast: AC Immune CEO, Andrea Pfeifer, at World Economic Forum

Join AC Immune CEO, Andrea Pfeifer, and top executives from Johnson & Johnson and Biogen, for Alzheimer’s: A Global Call for Action, a webcast chaired by Murali Doraiswamy of Duke University, during the World Economic...

Join AC Immune CEO, Andrea Pfeifer, and top executives from Johnson & Johnson and Biogen, for Alzheimer’s: A Global Call for Action, a webcast chaired by Murali Doraiswamy of Duke University, during the World Economic Forum in Davos, this Thursday 24 January at 4pm CET.

Webcast: AC Immune CEO, Andrea Pfeifer, at World Economic Forum

Join AC Immune CEO, Andrea Pfeifer, and top executives from Johnson & Johnson and Biogen, for Alzheimer’s: A Global Call for Action, a webcast chaired by Murali Doraiswamy of Duke...

Join AC Immune CEO, Andrea Pfeifer, and top executives from Johnson & Johnson and Biogen, for Alzheimer’s: A Global Call for Action, a webcast chaired by Murali Doraiswamy of Duke University, during the World Economic Forum in Davos, this Thursday 24 January at 4pm CET.

AC Immune's Nasdaq Opening Bell ceremony at CNBC

AC Immune's Nasdaq Opening Bell ceremony at CNBC

The woman who’s committed to curing Alzheimer’s disease

Link to interview
Andrea Pfeifer, CEO AC Immune, talked to CNN Money Switzerland about her leadership principles, her values, and what people like Nelson Mandela and Steve Jobs have taught her about being a good boss.
Teaser CNN...

Andrea Pfeifer, CEO AC Immune, talked to CNN Money Switzerland about her leadership principles, her values, and what people like Nelson Mandela and Steve Jobs have taught her about being a good boss.

Teaser CNN Money Switzerland:

Andrea Pfeifer is a woman on a mission. The CEO of the Lausanne-based, Nasdaq-listed Swiss biopharmaceutical AC Immune is determined to find breakthrough therapies for neurodegenerative diseases such as Alzheimer’s. Pfeifer – who as head of Nestlé’s Global Research managed a group of more than 600 people – took a risk in taking charge of a then unknown start-up. “I was going back to square zero,” she says, “with no business plan and no guarantee for success.” In this week’s Executive Talk, she tells Editor in Chief Urs Gredig about her leadership principles, her values, and what people like Nelson Mandela and Steve Jobs have taught her about being a good boss.

Andrea Pfeifer, CEO AC Immune, talked to CNN Money Switzerland about her leadership principles, her values, and what people like Nelson Mandela and Steve Jobs have taught her about being a good boss.

Teaser CNN Money Switzerland:

Andrea Pfeifer is a woman on a mission. The CEO of the Lausanne-based, Nasdaq-listed Swiss biopharmaceutical AC Immune is determined to find breakthrough therapies for neurodegenerative diseases such as Alzheimer’s. Pfeifer – who as head of Nestlé’s Global Research managed a group of more than 600 people – took a risk in taking charge of a then unknown start-up. “I was going back to square zero,” she says, “with no business plan and no guarantee for success.” In this week’s Executive Talk, she tells Editor in Chief Urs Gredig about her leadership principles, her values, and what people like Nelson Mandela and Steve Jobs have taught her about being a good boss.

Diversity requires Openness

AC Immune's CEO Andrea Pfeifer explains the success of the Company and her fascination with entrepreneurship. She talks about the significance of Switzerland as a business location and the 2018 SEF motto.
Original...

AC Immune's CEO Andrea Pfeifer explains the success of the Company and her fascination with entrepreneurship. She talks about the significance of Switzerland as a business location and the 2018 SEF motto.

Diversity requires Openness

AC Immune's CEO Andrea Pfeifer explains the success of the Company and her fascination with entrepreneurship. She talks about the significance of Switzerland as a business location and the...

AC Immune's CEO Andrea Pfeifer explains the success of the Company and her fascination with entrepreneurship. She talks about the significance of Switzerland as a business location and the 2018 SEF motto.

It takes Tau to Tangle

AC Immune’s partner Genentech has published an editorial which summarizes the biology of Alzheimer’s disease (AD) and describes the importance of tau as a target in AD. Written in an accessible and informative way, the...

AC Immune’s partner Genentech has published an editorial which summarizes the biology of Alzheimer’s disease (AD) and describes the importance of tau as a target in AD. Written in an accessible and informative way, the editorial also explains why selecting the right type of antibody is key as was recently published in Cell Reports by Gai Ayalon et al.

In 2006, AC Immune closed an exclusive out-licensing agreement for its anti-Abeta antibody program with Genentech, under which Genentech develops crenezumab for the treatment of Alzheimer's disease.

In 2012, AC Immune entered into a second exclusive worldwide license agreement and research collaboration with Genentech for the research, development and commercialization of AC Immune’s anti-Tau antibodies.

It takes Tau to Tangle

AC Immune’s partner Genentech has published an editorial which summarizes the biology of Alzheimer’s disease (AD) and describes the importance of tau as a target in AD. Written in an...

AC Immune’s partner Genentech has published an editorial which summarizes the biology of Alzheimer’s disease (AD) and describes the importance of tau as a target in AD. Written in an accessible and informative way, the editorial also explains why selecting the right type of antibody is key as was recently published in Cell Reports by Gai Ayalon et al.

In 2006, AC Immune closed an exclusive out-licensing agreement for its anti-Abeta antibody program with Genentech, under which Genentech develops crenezumab for the treatment of Alzheimer's disease.

In 2012, AC Immune entered into a second exclusive worldwide license agreement and research collaboration with Genentech for the research, development and commercialization of AC Immune’s anti-Tau antibodies.